Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Colorcon
Mallinckrodt
Baxter
Express Scripts

Last Updated: October 6, 2022

Details for Patent: 9,469,643


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,469,643 protect, and when does it expire?

Patent 9,469,643 protects ZYDELIG and is included in one NDA.

This patent has thirty-six patent family members in thirty-one countries.

Summary for Patent: 9,469,643
Title:Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e
Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Inventor(s): Carra; Ernest (Foster City, CA), Gerber; Michael (Oakland, CA), Shi; Bing (Redwood City, CA), Sujino; Keiko (Edmonton, CA), Tran; Duong (Edmonton, CA), Wang; Fang (Foster City, CA), Evarts; Jerry B. (Seattle, WA)
Assignee: Gilead Calistoga, LLC. (Foster City, CA)
Application Number:14/493,261
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 9,469,643

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,469,643

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 090253 See Plans and Pricing
Australia 2013203620 See Plans and Pricing
Brazil 112014021935 See Plans and Pricing
Canada 2864305 See Plans and Pricing
Chile 2014002358 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Dow
Baxter
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.